| 杨尚芝,金 红,李 娟,牛玉伟.坤泰胶囊联合米非司酮治疗围绝经期功能失调性子宫出血的疗效及对bFGF、VEGF水平的影响[J].现代生物医学进展英文版,2023,(17):3340-3344. |
| 坤泰胶囊联合米非司酮治疗围绝经期功能失调性子宫出血的疗效及对bFGF、VEGF水平的影响 |
| Therapeutic Effects of Kuntai Capsule Combined with Mifepristone on Perimenopausal Dysfunctional Uterine Bleeding and its Influence on bFGF and VEGF Levels |
| Received:February 23, 2023 Revised:March 18, 2023 |
| DOI：10.13241/j.cnki.pmb.2023.17.027 |
| 中文关键词: 坤泰胶囊 米非司酮 围绝经期 功能失调性子宫出血 疗效评价 碱性成纤维细胞生长因子 血管内皮细胞生长因子 |
| 英文关键词: Kuntai capsule Mifepristone Perimenopause Dysfunctional uterine bleeding Efficacy evaluation Basic fibroblast growth factor Vascular endothelial growth factor |
| 基金项目: |
|
| Hits: 549 |
| Download times: 333 |
| 中文摘要: |
| 摘要 目的：分析坤泰胶囊联合米非司酮治疗围绝经期功能失调性子宫出血（DUB）的疗效及对碱性成纤维细胞生长因子（bFGF）、血管内皮细胞生长因子（VEGF）水平的影响。方法：选取2021年10月-2022年10月在合肥市第一人民医院滨湖院区妇科门诊就医的88例围绝经期DUB患者作为研究对象，采用随机数据表法将其分为研究组和对照组，每组各44例，两组患者入组后均给予常规对症治疗，对照组患者在此基础上给予口服米非司酮胶囊，用量为每日1次，每次10 mg。研究组患者在对照组疗法的基础上给予口服坤泰胶囊，用量为每日3次，每次2 g。两组患者均连续服用3个月。对两组患者的疗效指标及治疗前和治疗3个月时的子宫内膜厚度、血清卵泡刺激素（FSH）、黄体生成素（LH）、泌乳素（PRL）、雌二醇（E2）、bFGF、VEGF水平进行比较。对两组患者治疗期间的不良反应进行比较。结果：研究组患者的疗效等级分布优于对照组，有效率高于对照组（P<0.05）。两组患者治疗前的子宫内膜厚度及血清性激素、bFGF、VEGF水平的差异均无统计学意义（P>0.05），在治疗3个月末，两组患者的子宫内膜厚度及血清FSH、LH、PRL、E2水平均较治疗前降低，血清bFGF、VEGF水平均较治疗前升高（P<0.05），研究组患者在治疗3个月末的子宫内膜厚度及血清FSH、LH、PRL、E2水平均低于对照组，血清bFGF、VEGF水平均高于对照组（P<0.05）。两组不良反应均为轻度，在未经治疗的情况下患者可耐受，未见因不良反应而中断治疗的患者。两组各项不良反应发生率和不良反应总发生率的差异均无统计学意义（P>0.05）。结论：在围绝经期DUB的治疗中，采用坤泰胶囊联合米非司酮的中西医治疗方案，在临床疗效优于单用米非司酮方案，能够更加显著地改善血清激素水平、抑制子宫内膜增生、提升bFGF、VEGF等血管生成因子的表达水平。 |
| 英文摘要: |
| ABSTRACT Objective: To analyze the therapeutic effects of Kuntai capsule combined with mifepristone on perimenopausal dysfunctional uterine bleeding (DUB) and its influence on the levels of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF). Methods: 88 patients with perimenopausal DUB who were treated in the gynaecological clinic of Hefei First People's Hospital from October 2021 to October 2022 were selected as the study subjects. They were divided into a study group and a control group by random data table method. 44 patients were included into each group. The patients in the two groups were treated with routine symptomatic treatment after entering the group. The patients in the control group were given oral mifepristone capsules, with the dosage of 10 mg each time, once a day. On the basis of the treatment in the control group, the patients in the study group were treated with Kuntai capsule orally, with the dosage of 2 g, three times a day. The patients in the two groups were treated with continuously for 3 months. The therapeutic indexes as well as the endometrial thickness, the serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), estradiol (E2), bFGF and VEGF before and after treatment for 3 months between the patients in the two groups were compared. The adverse events during treatment between the patients in the two groups were compared. Results: The distribution of efficacy grade in the study group was better than that in the control group, and the effective rate was higher than that in the control group (P<0.05). There was no statistically significant difference in the endometrial thickness and serum levels of sex hormone, bFGF and VEGF between the two groups before treatment (P>0.05). At the end of 3 months of treatment, the endometrial thickness and the serum levels of FSH, LH, PRL and E2 in the two groups were lower than those before treatment, and the serum levels of bFGF and VEGF were higher than those before treatment (P<0.05). The endometrial thickness and the serum levels of FSH, LH, PRL and E2 at the end of 3 months of treatment of the patients in the study group were lower than those in the control group, and the levels of bFGF and VEGF in serum were higher than those in the control group(P<0.05). The adverse reactions in both groups were mild and could be tolerated by patients without treatment. There was no patient who interrupted treatment due to adverse reactions. There was no significant difference between the two groups in the incidence of various adverse events and the total incidence of adverse events (P>0.05). Conclusion: In the treatment of perimenopausal DUB, the traditional Chinese and western medicine treatment scheme of Kuntai capsule combined with mifepristone is superior to that of mifepristone alone in clinical efficacy, which can improve the serum hormone levels, inhibit endometrial hyperplasia and increase the expression levels of angiogenic factors such as bFGF, VEGF more significantly. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
